CTI BioPharma (CTIC), Baxalta Terminate Pacritinib Licensing Agreement (SHPG)

October 24, 2016 6:34 AM EDT Send to a Friend
CTI BioPharma (NASDAQ: CTIC) disclosed the following in a U.S. SEC filing on Monday:Item 1.01. Entry into a Material Definitive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login